Online inquiry

IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12642MR)

This product GTTS-WQ12642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RSPO3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_032784.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84870
UniProt ID Q9BXY4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4496MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ12680MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ11977MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ11049MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ6224MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ4887MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ4580MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ9306MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMP-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW